Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 07/29 05:30:49 pm
247.5 CHF   +0.81%
06:30a ROCHE : oeuvre management assignment for the lighting of the cathedr..
07/28 ROCHE : Township adopts roche phase 1 redevelopment plan
07/28 ROCHE : emicizumab continued to show promising safety and efficacy p..
News SummaryMost relevantAll newsSector news 

FDA Approves Breast-Cancer Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 06:05pm CEST

--Drug packs Roche's Herceptin with chemotherapy agent

--Drug approved for use as a first-line, or initial treatment for advanced breast cancer

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent, and is meant to treat certain types of breast cancer that have spread to other parts of the body.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales of up to 5%.

Analysts said the approval was broader than expected. The drug can be marketed for initial treatment rather than just in patients who've tried other therapies, creating a "significantly larger patient population," said Simos Simeondis, an analyst at Cowen and Company.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

Agents like Kadcyla are called antibody-drug conjugates and they are the focus of intense interest in the pharmaceutical industry. Roche's Genentech unit has 25 such agents under development for different cancers, including eight in human studies.

The first such agent to gain FDA approval was Seattle Genetics Inc.'s (>> Seattle Genetics, Inc.) Adcetris, for Hodgkin's Lymphoma and another rare cancer. That company and ImmunoGen are each collaborating with big pharmaceutical firms including Bayer AG (BAYRY, BAYN.XE), Eli Lilly & Co. (>> Eli Lilly & Co.), GlaxoSmith Kline PLC (GSK, GSK.LN), Pfizer Inc. (>> Pfizer Inc.), Sanofi (>> Sanofi SA) to develop several types of new cancer drugs.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The study showed women receiving Kadcyla lived for an average of 31 months, which was about six months longer than women being treated with Xeloda and Tykerb.

However, like other cancer drugs Kadcyla has the potential to cause serious and life-threatening side effects from liver damage or heart problems. The drug can also cause severe birth defects so doctors need to make sure women of child-bearing age aren't pregnant before administering the product.

--Joseph Walker contributed to this story.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
06:30a ROCHE : oeuvre management assignment for the lighting of the cathedral our lady ..
07/28 Chugai and Galderma Announce Global License Agreement for Nemolizumab CIM331,..
07/28 ROCHE : Sources Sought Notice - 65-- Roche Diagnostics Corp Histology Supplies f..
07/28 ROCHE : Township adopts roche phase 1 redevelopment plan
07/28 ROCHE : emicizumab continued to show promising safety and efficacy profile in lo..
07/27DJExperimental Alzheimer's Drug Fails in Trial
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/27 ROCHE : Architectural, engineering and planning services
07/22 ROCHE : F. Hoffmann-La Roche Announces Half Year Results 2016
07/22 ROCHE : Diagnostics Operations Assigned Patent
More news
Sector news : Pharmaceuticals - NEC
10:44pDJTech Stocks Up On Google Earnings - Tech Roundup
07:33pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
04:26pDJABBVIE : Results Boosted by Humira, Pipeline Growth
04:17pDJABBVIE : Results Boosted by Humira, Pipeline Growth
02:26pDJMerck Revenue Rises on Cancer, Hepatitis Treatments
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:36a Roche Quietly Takes Hemophilia Lead
07/28 BIOMARIN : Product Announcements Increase Long Term Potential And Price Target
07/28 Roche's hemophilia candidate emicizumab shows encouraging results in early-st..
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 Puma Files, And The Battle Begins
Financials ( CHF)
Sales 2016 51 205 M
EBIT 2016 17 846 M
Net income 2016 11 515 M
Debt 2016 10 958 M
Yield 2016 3,47%
P/E ratio 2016 18,17
P/E ratio 2017 16,41
EV / Sales 2016 4,34x
EV / Sales 2017 4,03x
Capitalization 211 287 M
More Financials
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 298  CHF
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Daniel O'Day COO-Roche Pharmaceuticals Division
Roland Diggelmann COO-Roche Diagnostics Division
Alan Hippe Chief Financial & Information Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.99%215 597
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
More Results